Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 10/20 | 0.61 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSH | P09668 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307858 | 0.95 | KISS1R (0.58) | CXCR4KISS1RPTGS1CAPN1CTSB | |
| SCHEMBL30567818 | 0.95 | KISS1R (0.58) | CXCR4KISS1RPTGS1CAPN1CTSB | |
| Hydrochloric Acid SCHEMBL11644315 | 0.94 | KISS1R (0.57) | CXCR4KISS1RPTGS1CAPN1CTSB | |
| SCHEMBL5167427 | 0.92 | KISS1R (0.67) | CXCR4KISS1RPTGS1 | |
| SCHEMBL5167437 | 0.92 | KISS1R (0.67) | CXCR4KISS1RPTGS1 | |
| SCHEMBL29833824 | 0.92 | CXCR4 (0.52) | CXCR4KISS1RPTGS1CTSLCTSH | |
| SCHEMBL30007711 | 0.91 | KISS1R (0.62) | CXCR4KISS1RCAPN1CTSBNTSR2 | |
| SCHEMBL30567819 | 0.91 | KISS1R (0.64) | CXCR4KISS1RPTGS1 | |
| SCHEMBL11593491 | 0.89 | KISS1R (0.56) | CXCR4KISS1RPTGS1CAPN1CTSB | |
| SCHEMBL29942444 | 0.89 | KISS1R (0.56) | CXCR4KISS1RPTGS1CAPN1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240033320-A1 | IMMUNORHELIN COMPOUNDS FOR INTRACELLULAR INFECTIONS | ISR Immune System Regulation Holding AB (publ) (SE) | 2024-02-01 | — | — | US | claimed |
| US-11564969-B2 | Immunorhelin compounds for intracellular infections | ISR Immune System Regulation Holding AB (publ) (SE) | 2023-01-31 | — | — | US | claimed |
| US-20240033320-A1 | IMMUNORHELIN COMPOUNDS FOR INTRACELLULAR INFECTIONS | ISR Immune System Regulation Holding AB (publ) (SE) | 2024-02-01 | — | — | US | disclosed |
| US-20230118205-A1 | NOVEL COMPOUNDS (IMMUNORHELINS) | ISR IMMUNE SYSTEM REGULATION HOLDING AB PUBL (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11564969-B2 | Immunorhelin compounds for intracellular infections | ISR Immune System Regulation Holding AB (publ) (SE) | 2023-01-31 | — | — | US | disclosed |
| US-11434258-B2 | Compounds (immunorhelins) | ISR Immune System Regulation Holding AB (SE) | 2022-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230118205-A1 | NOVEL COMPOUNDS (IMMUNORHELINS) | GNRHR, FSHR, LHCGR | CXCR4 281/4885KISS1R 20/4885PTGS1 3702/4885 |
| US-20240033320-A1 | IMMUNORHELIN COMPOUNDS FOR INTRACELLULAR INFECTIONS | GNRHR, GHRHR, FSHR | CXCR4 633/4885KISS1R 40/4885PTGS1 3887/4885 |
| US-11564969-B2 | Immunorhelin compounds for intracellular infections | GNRHR, GHRHR, FSHR | CXCR4 633/4885KISS1R 40/4885PTGS1 3887/4885 |
| US-11434258-B2 | Compounds (immunorhelins) | GNRHR, FSHR, LHCGR | CXCR4 291/4885KISS1R 19/4885PTGS1 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.